NEW YORK, December 10, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Receptos, Inc. (NASDAQ: RCPT), MEDNAX, Inc. (NYSE: MD), CombiMatrix Corporation (NASDAQ: CBMX), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Receptos, Inc. Research Report
On November 26, 2013, Receptos, Inc. (Receptos) announced the appointment of Christian Waage as the Senior Vice President and General Counsel of the Company. Receptos said that Mr. Waage joins the Company from Websense Inc., where he served as Vice President and General Counsel from 2012 until its acquisition in 2013. Commenting on the appointment, Faheem Hasnain, President and CEO of Receptos said, "Christian brings tremendous legal experience both in the biotechnology sector and more broadly. Christian's leadership and guidance will support our efforts as we execute on our development programs, including our ongoing Phase 2/3 study of RPC1063 in relapsing multiple sclerosis as well as our Phase 2 study in ulcerative colitis." The Full Research Report on Receptos, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
MEDNAX, Inc. Research Report
On December 5, 2013, MEDNAX, Inc. (MEDNAX) announced that its Board of Directors has authorized a two-for-one split of the Company's common stock. According to the Company, shareholders of record on the effective date of December 19, 2013 will receive one additional share of MEDNAX common stock for each share of MEDNAX common stock then held, without any further action on the part of MEDNAX's shareholders. The Company reported that shareholders do not need to exchange existing stock certificates and will receive additional shares as a result of the stock split through the Direct Registration System on December 20, 2013. MEDNAX also stated that its Board of Directors has authorized the amendment of the Company's Articles of Incorporation to increase the number of authorized shares of common stock from 100 million to 200 million, in order to complete the stock split. The Full Research Report on MEDNAX, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
CombiMatrix Corporation Research Report
On December 5, 2013, CombiMatrix Corporation (CombiMatrix) announced that the American College of Obstetricians and Gynecologists (ACOG) has issued new guidelines indicating that chromosomal microarray analysis (CMA) is now recommended as the first-line genetic test in pregnancies showing fetal abnormalities on an ultrasound screen. CombiMatrix reported that CMA is a DNA-based method of prenatal genetic testing which can identify major chromosomal defects such as Down syndrome, as well as many other genetic defects that are too small to be detected by karyotyping. Mark McDonough, President and CEO of CombiMatrix, stated, "We believe this new guidance from ACOG recommending CMA as the first-line test when an ultrasound reveals one or more major fetal abnormalities is a significant milestone in the evolution of genetic testing for fetal abnormalities, but one that we had expected based on the clinical data from recently published studies." The Full Research Report on CombiMatrix Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Anacor Pharmaceuticals, Inc. Research Report
On November 12, 2013, Anacor Pharmaceuticals, Inc. (Anacor) announced positive results from its maximal use systemic exposure (MUSE) study of its boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728, in pediatric and adolescent patients with atopic dermatitis. According to Anacor, the results of the study demonstrate that AN2728 Ointment, 2% appears to be safe, well-tolerated, and efficacious when applied twice daily to patients, ages two to 18 years with atopic dermatitis affecting a very large percentage of their body surface area. Commenting on the results, David Perry, CEO of Anacor, said, "We are pleased to see the efficacy and safety profile demonstrated in this study, as it represents the final significant hurdle before holding an End of Phase 2 meeting with the FDA." The Full Research Report on Anacor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Idera Pharmaceuticals, Inc. Research Report
On December 4, 2013, Idera Pharmaceuticals, Inc. (Idera) announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its Investigational New Drug (IND) application by the US Food and Drug Administration (FDA). Idera reported that the objectives of the clinical trial are to evaluate the compound's safety, tolerability, and potential clinical activity. Robert D. Arbeit, M.D., Vice President of Clinical Development at Idera, explained, "The MYD88 L265P mutation is highly characteristic of Waldenström's macroglobulinemia and has been identified as potentially oncogenic. IMO-8400 targets the activation of the TLR signaling pathway and represents a novel approach to the treatment of these patients." The Full Research Report on Idera Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner